Company intelligence / Profile preview

BioSciences Acquisition

Chelmsford, MA, USA

Ownership: Private
Development stage: Other

Overview

BIOS Acquisition Corp. was a special purpose acquisition company (SPAC) focused on the healthcare and life sciences sectors. Led by CEO Ross Haghighat, the company was established to identify and merge with a high-growth biotechnology or medical technology firm. In May 2023, BIOS announced a definitive merger agreement with Avertix Medical, a developer of the FDA-approved Guardian System for heart attack detection. However, the transaction was mutually terminated in October 2023 due to unfavorable market conditions, and the company subsequently initiated a liquidation and dissolution process.

Industry: Investors

Partnerships

Avertix Medical

Beyond the preview

Go deeper on BioSciences Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSciences Acquisition.

Explore the full profile